SCHEMBL5339174

SCHEMBL5339174

Cc1cc(NC(=O)Nc2ccc(Oc3ccnc(-c4cnn(C)c4)n3)cc2)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
MAPT P10636 2/20 0.51
HSD17B10 Q99714 1/20 0.51
RAF1 P04049 1/20 0.47
KDR P35968 12/20 0.47
NTRK1 P04629 1/20 0.47
RET P07949 1/20 0.47
EPHB2 P29323 1/20 0.47
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
AURKA O14965 1/20 0.44
FLT3 P36888 1/20 0.44
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5333938 0.82 KDR (0.54) KDRNTRK1AURKAFLT3AURKB
SCHEMBL14468720 0.80 KDR (0.43) KDRNTRK1AURKAAURKBCSF1R
SCHEMBL5345816 0.79 KDR (0.65) KDRNTRK1RETAURKAFLT3
SCHEMBL5429189 0.79 KDR (0.73) RAF1KDRNTRK1RETEPHB2
SCHEMBL5454230 0.77 NTRK1 (0.56) KDRNTRK1RETEPHB2AURKB
SCHEMBL5457893 0.76 NTRK1 (0.63) KDRNTRK1RETEPHB2AURKA
SCHEMBL5442522 0.74 NTRK1 (0.58) KDRNTRK1RETEPHB2CSF1R
SCHEMBL573613 0.73 RAF1 (0.64) RAF1KDRNTRK1RETEPHB2
SCHEMBL5452721 0.73 NTRK1 (0.72) NPC1MAPTKDRNTRK1RET
SCHEMBL5338760 0.72 NTRK1 (0.66) NPC1MAPTKDRNTRK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 SMN1; SMN2 3885/4885RAB9A 1640/4885NPC1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.